Podcast Episodes

Episode 277: NMIBC Discussion at #UromigosLive 2023

Season 2 Episode 277

Tom is joined by Sam Chang, Sia Daneshmand, and Petros Grivas to discuss new therapies in non-muscle invasive bladder cancer, including those for BCG…

2 years, 11 months ago

View Episode

Episode 276: ESMO 2023 Highlights

Season 2 Episode 276

Silke Gillessen joins Tom and Brian to give a summary of the meeting,

3 years ago

View Episode

Episode 275: Live meeting preview for #UromigosLive 2023 in Nashville

Season 2 Episode 275

Brian and Tom discuss the benefits and risks of participating in the upcoming meeting . Uncertainty around it’s success are highlighted . Methods of …

3 years ago

View Episode

Episode 274: ESMO 2023 STEAP1/BiTE in CRPC shows promise

Season 2 Episode 274

Kevin Kelly described a Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) bispecific T cell engager showing activity in a phase 1 trial…

3 years ago

View Episode

Episode 273: ESMO 2023 - Toripalimab and axitinib in clear cell RCC

Season 2 Episode 271

Toripalimab plus axitinib as first-line treatment option for advanced RCC by Xinan Sheng

3 years ago

View Episode

Episode 272: ESMO 2023 - EV302 and CM901 in 1st line bladder cancer

Season 2 Episode 269

Michiel van der Heijden and Tom discuss EV302 (EVP) and CM901 (chemo/nivo)

3 years ago

View Episode

Episode 271: ESMO 2023 - THOR: Erdafitinib in bladder cancer

Season 2 Episode 270

Yohann Loriot described the 2 Thor randomised phase 3 studies

3 years ago

View Episode

Episode 270: ESMO 2023 - Belzutifan in renal cancer

Season 2 Episode 270

Lisa Pickering discusses the 2 randomised trial and the 1st line combination study in renal cancer

3 years ago

View Episode

Episode 269: ESMO 2023 - antibody drug conjugate doublets in UC

Season 2 Episode 267

Brad McGregor discuses the DAD trial exploring this combo for the 1st time

3 years ago

View Episode

Episode 268: ESMO 2023 - Enzalutamide and 177Lu-PSMA-617 in CRPC with Louise Emmett

Season 2 Episode 272

Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1…

3 years ago

View Episode